Fluorinated derivatives of 2-phenyl-3-hydroxy-4(1H)-quinolinone as tubulin polymerization inhibitors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73601222" target="_blank" >RIV/61989592:15110/20:73601222 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15310/20:73601222

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0223523420301434?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0223523420301434?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejmech.2020.112176" target="_blank" >10.1016/j.ejmech.2020.112176</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Fluorinated derivatives of 2-phenyl-3-hydroxy-4(1H)-quinolinone as tubulin polymerization inhibitors

Popis výsledku v původním jazyce

The previous studies of the derivatives of 2-phenyl-3-hydroxy-4(1H)-quinolinone (3-HQs) recognized these compounds to exhibit anticancer activity in vitro in the native state [[1], [2], [3], [4], [5], [6], [7]] or as mixed-ligand complexes with various metals [[8], [9], [10], [11], [12]]. Although these studies described the number of derivatives to have exciting anticancer activity, only two papers revealed a possible molecular target. In the first study, Sui et al. [13] reported the inhibition of topoisomerase as an expected molecular target. The authors found some derivatives with higher activity against mammalian topoisomerase than ellipticine. Recently published interaction of other 3-HQs derivatives with elongation factor eEF1A1 inside the cancer cells revealed another possible mechanism of anticancer activity [14].

Název v anglickém jazyce

Fluorinated derivatives of 2-phenyl-3-hydroxy-4(1H)-quinolinone as tubulin polymerization inhibitors

Popis výsledku anglicky

The previous studies of the derivatives of 2-phenyl-3-hydroxy-4(1H)-quinolinone (3-HQs) recognized these compounds to exhibit anticancer activity in vitro in the native state [[1], [2], [3], [4], [5], [6], [7]] or as mixed-ligand complexes with various metals [[8], [9], [10], [11], [12]]. Although these studies described the number of derivatives to have exciting anticancer activity, only two papers revealed a possible molecular target. In the first study, Sui et al. [13] reported the inhibition of topoisomerase as an expected molecular target. The authors found some derivatives with higher activity against mammalian topoisomerase than ellipticine. Recently published interaction of other 3-HQs derivatives with elongation factor eEF1A1 inside the cancer cells revealed another possible mechanism of anticancer activity [14].

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

ISSN

0223-5234

e-ISSN

—

Svazek periodika

192

Číslo periodika v rámci svazku

April 15 2020

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

9

Strana od-do

"'nestránkováno'"

Kód UT WoS článku

000523563100017

EID výsledku v databázi Scopus

2-s2.0-85080081774